Elder Pharma in alliance with Laboratorios Farmacéuticos

1971 Investors following Elder Pharma. Share this News with them.

0

Like this story, share it with millions of investors on M3

Elder Pharma in alliance with Laboratorios Farmacéuticos

Elder Pharmaceuticals enters into alliance with Laboratorios Farmacéuticos Rovi, S.A of Spain for Anti Thrombotics

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS Elder Pharma's traditional biz to spur growth Elder Pharma Q3 net profit at Rs 14.57cr Elder Pharma in alliance with Farmaka of Switzerland ALSO READ See latest News about Elder Pharma See previous management interviews See what other Experts & Brokerages are saying about Elder Pharma Elder Pharma BSE | NSE 25/05/12 Are Mutual Funds betting on Elder Pharma?

The Rs 400 crore Elder Pharmaceuticals Limited has entered into an alliance with M/s LABORATORIOS FARMACÉUTICOS ROVI, S.A of Spain to market advanced heparins (anti-thrombotics) in India for treatment and prevention of thrombo-embolic Venous diseases like deep vein thrombosis and pulmonary embolism. Established in Spain in 1946 M/s Laboratorios Farmaceuticos Rovi, S.A (ROVI) is a Euro 100 million research-backed pharmaceuticals company selling its products in more than 20 countries. Rovi invests 18% of its turnover in R & D and also exports science & technology to over 30 countries. ROVI pursues two very specialized lines of research, concentrating its efforts on the prevention and treatment of venous thrombo-embolic disease and contrast agents for image diagnosis.

To begin with, the joint initiative between Elder and Rovi shall see the introduction in India of the patented, US FDA approved product Bemiparin a second-generation low molecular weight heparin (LMWH) for the prevention & treatment of thrombo-embolic venous diseases. Bemiparin has consolidated its position in the anti-thrombotic market as the second most sold LMWH in Spain with a market share of 25% during 2006. In India, Bemiparin would be launched with the brand name of HIBOR shortly.

The total anti-thrombotic market in India is Rs. 130 crore with products mainly from the MNCs like Sanofi, Aventis, Knoll, Pharmacia, Novartis, etc. Elder hopes to garner between 8% & 10% market share in the first year of launch itself.

"Anti-thrombotics constitute an important niche market for Elder Pharmaceuticals and we wanted to bring the most effective product range in this category to India" says Alok Saxena, Director (International), Elder Pharmaceuticals Limited.

Sourced From: Synergy Public Relations